Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $46.78, marking a +2.7% move from the previous day.
The Big 3: CRSP, OKLO, GME
Mike Shorr (@ProsperTradingAcademy) looks to manage risk levels in his 3 example options trades. For Crispr Therapeutics (CRSP), he's looking at low-implied volatility in the gene-editing biotech company.
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line.
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $44.43, representing a +2.87% change from its previous close.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million?
CRSP's innovative pipeline shines, but the biotech does face regulatory risks and fierce competition.
Crispr Therapeutics: Betting On A One-Shot Future
Crispr Therapeutics AG is transitioning to a commercial company, with CASGEVY's rollout and a robust pipeline in cardiovascular, autoimmune, and oncology driving long-term potential. The cardiovascular franchise, especially CTX-310 and CTX-320, offers blockbuster potential with best-in-class efficacy and a compelling one-time treatment value proposition. Recent partnerships, like Sirius Therapeutics, expand Crispr's multi-modal platform and open new multi-billion dollar market opportunities in siRNA and beyond.
Biotech Stock for Options Bears to Target Right Now
Biotech stock Crispr Therapeutics Inc's (NASDAQ:CRSP) June rally appears to be coming to an end.
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
